Coronavirus vaccine: The Covid-19 vaccine candidate of Novavax is being studied in two ongoing pivotal Phase 3 clinical trials: in the United States and Mexico, as well as in the United Kingdom

In this meeting, the NTAGI will review the World Health Organisation's (WHO) recommendation to extend the gap between two doses of the AstraZeneca- Oxford vaccine from 4 weeks to 8-12 weeks

Chhattisgarh CM had raised two primary concerns regarding Covaxin -- inhibitions on incomplete trials and absence of \"expiration date\". Dr Vardhan says vaccine approved after due evaluation of pre-clinical and clinical trial data and that expiry date is mentioned on its label

Coronavirus vaccine: Pfizer was the first pharmaceutical company to seek EUA from Drugs Controller General of India (DCGI) after its vaccine was approved in the UK and Bahrain

Serum Institute of India CEO Adar Poonawalla said the company's tie-up with American vaccine developer Novavax has published 'excellent efficacy results'

India has no data on jobs lost and businesses shut; no estimate of how many would have slipped into poverty or how income, health and education inequalities would have risen due to the pandemic. How will the Budget 2021 allocate resources appropriately to revive growth and bring development?

While Aurobindo Pharma has committed an investment of Rs 3,039 crore to set up production facilities for three eligible products, Kinvan will invest Rs 447.17 crore to build 300 MT capacity plant to produce Clavulanic Acid

There were no serious side effects in the participants enrolled for the phase 1 trial of Covaxin, according to the results published in The Lancet

Details on the size of the deal or the price per dose COVAX would pay were not immediately clear, but the sources said the allotment would likely be relatively small

If allowed to go ahead, this would be the first trial of any coronavirus vaccine in Bangladesh and could give the densely-populated country of more than 160 million faster access to the shot for mass use

Bharat Biotech is developing the intranasal vaccine in partnership with the Washington University School of Medicine and US-based vaccine maker Ocugen

The Subject Expert Committee (SEC) of the Central Drugs Standard Control Organisation (CDSCO) on Tuesday recommended Bharat Biotech's intranasal vaccine for conducting phase 1 clinical trials for the coronavirus

Close on the heels of some adverse incidents being reported, a detailed fact sheet released by Bharat Biotech says those with bleeding disorders or on blood thinners should avoid taking the shot for now

Tata Steel, ArcelorMittal Nippon Steel India and Rashtriya Ispat Nigam Ltd said they will continue to support the government in the nationwide drive and will wait till vaccines are available for corporates

As of now, the pre-condition for any vaccine to be implemented in India is that you have to do a bridging trial, said Niti Aayog member VK Paul who also heads National Expert Group On Vaccine Administration for COVID-19 (NEGVAC)

The pre-prints or preliminary reports of research work related to Covaxin, which are yet to be peer-reviewed are already posted on pre-print servers like bioRxiv, medRxiv and Research Square

A team from Precisa Medicamentos visited the Bharat Biotech's Hyderabad facility last week to discuss potential export possibilities of Covaxin with Chairman Dr Krishna Ella on the January 7-8

Several states have made all necessary preparations for the first phase of the exercise comprising identifying vaccination sites and registration of healthcare and other frontline workers

Coronavirus vaccination drive: The letter alleged irregularities and ethical violations in the conduct of the clinical trial of Covaxin by the People's College of Medical Sciences & Research Centre, Bhopal

Bharat Biotech revealed that one of the participants for Phase III trials passed away on December 21, 2020, and the death was reported to the People's College of Medical Sciences and Research Centre by the son of the deceased